B7-H3 ADC clinical data released:

Article source: Medical Rubik's Cube Pro

B7-H3 is a member of the B7 family of immunoregulatory molecules.

B7-H3 mechanism of action (Source: MacroGenics)

MGC018 is an ADC targeting B7-H3, formed by anti-B7-H3 humanized IgG1/kappa monoclonal antibody through a cleavable linker coupled to the prodrug seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA), with an average DAR of ~2.

MGC018 structure (Source: MacroGenics)

At the 2021 ASCO annual meeting, the biopharmaceutical company MacroGenics announced the preliminary safety and anti-tumor activity data of the ongoing phase I dose-escalation clinical trial of MGC018 (NCT03729596)

mCRPC patient data (Source: MacroGenics)

The results of the analysis showed that MGC018 showed preliminary evidence of anti-tumor activity, especially in patients with advanced metastatic castration-resistant prostate cancer (mCRPC), and 5 out of 9 mCRPC patients had prostate-specific antigen observed during dose escalation therapy.

Melanoma patient data (Source: MacroGenics)

During the dose escalation process, 3 melanoma patients received 4.

Safety data (Source: MacroGenics)

In terms of safety, as of May 3, 2021, in the 0.

Preclinical data of combined PD-1 antibody (Source: MacroGenics)

In addition to the above data, MacroGenics also announced the preclinical research data of MGC018 combined with PD-1 antibody

Note: The original text has been deleted

Reference materials:

1# MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting (Source: MacroGenics)